Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × defactinib × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Melanoma 1 Glioblastoma 1 Brain Neoplasms 1

Interventions

Temozolomide 65 Radiotherapy 26 Bevacizumab 23 Carboplatin 12 Radiation 11 pembrolizumab 10 Irinotecan 7 Carmustine 7 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 Nivolumab 5 Everolimus 5 temsirolimus 4 atezolizumab 4 Vorinostat 4 Radiotherapy, Intensity-Modulated 4 Lomustine 4 Aminolevulinic Acid 4 tipifarnib 3 fludarabine 3 Sirolimus 3 Radiotherapy, Conformal 3 Paclitaxel 3 Magnetic Resonance Spectroscopy 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3 Drug Therapy 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06630260 2026-01-21

5G-RUBY

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡